Form 4 for PBYI PUMA BIOTECHNOLOGY, INC.
Accepted 2022-06-21 00:00:00 ET · period of report 2022-06-16 · accession 0001437749-22-015527 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-06-21 | 2022-06-16 | PBYI | Stuglik Brian M | Dir | S - Sale | $2.69 | -13.0K | 41.9K | -24% | -$35.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-16 | S | D | 13,000 | $2.69 | 41,858 | D | — | — | (F1) These shares were sold pursuant to a Rule 10b5-1 trading plan. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.614 to $2.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |